Charlotte Robinson

DocwireNews

Thermo Fisher Scientific has introduced a pretransplant risk assessment assay to help determine the risk of early acute rejection in kidney transplant recipients. The test provides data that may inform a more personalized approach to post-transplant immunosuppression management.&ldquo;Our One Lambda Pre-Transplant Risk Assessment (PTRA) Assay is the first test of its kind to provide a risk score for early acute rejection based on a patient&rsquo;s unique gene profile prior to transplant,&rdquo; explained Chris McCloskey, director of transplant services at Thermo Fisher Scientific.Routine standardized immunosuppression protocols based on broad clinical and demographic features are effective in reducing overall rates of kidney rejection. However, they may result in over-immunosuppression, which may lead to serious complications, poor long-term outcomes, and substantial costs to the health care system.The PTRA Assay uses an mRNA signature of 29 markers to help stratify patients into high- and low-risk categories for early acute rejection. In a recent clinical validation study, patients with high PTRA scores were six times more likely to experience early acute rejection than patients with low-risk scores, which was statistically significant. The test also showed superior prognostic accuracy compared with risk factors, such as high positive panel-reactive antibodies and the number of human leukocyte antigen mismatches, which were not shown to predict early acute rejection.&nbsp;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

New Test Helps Predict Early Acute Rejection in Kidney Transplant Recipients

Kidney Transplantation

A new pretransplant risk assessment assay by Thermo Fisher Scientific may help determine the risk of early acute kidney transplant rejection.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe